Suchergebnisse - "Fuglsang, Anders"

PubPharm (114)

1

Structure of the TnsB transposase-DNA complex of type V-K CRISPR-associated transposon

enthalten in: Nature communications | 2022

von Tenjo-Castaño, F. | Sofos, N. | López-Méndez, B. | +4

2

Structure of the TnsB transposase-DNA complex of type V-K CRISPR-associated transposon

enthalten in: bioRxiv.org | 2022

von Tenjo-Castaño, F. | Sofos, N. | Lopéz-Méndez, B. | +4

3

Intragenic codon usage in proteobacteria : Translational selection, IS expansion and genomic shrinkage

enthalten in: Gene | 2022

von Fuglsang, A.

4

Increased Patient's Risk Associated with the Canadian Bioequivalence Guidance Due to Outlier Removal

enthalten in: Therapeutic innovation & regulatory science | 2022

von Fuglsang, A.

5

Structure of the mini-RNA-guided endonuclease CRISPR-CasΦ3

enthalten in: bioRxiv.org | 2021

von Carabias, A. | Fuglsang, A. | Temperini, P. | +5

6

Mitigation of the convergence issues associated with semi-replicated bioequivalence data

enthalten in: Pharmaceutical statistics | 2021

von Fuglsang, A.

7

Increased Patient’s Risk Associated with the Canadian Bioequivalence Guidance Due to Outlier Removal

enthalten in: Therapeutic innovation & regulatory science | 2021

von Fuglsang, A.

8

Increased Patient’s Risk Associated with the Canadian Bioequivalence Guidance Due to Outlier Removal

enthalten in: Therapeutic innovation & regulatory science | 2021

von Fuglsang, A.

9

Increased Patient’s Risk Associated with the Canadian Bioequivalence Guidance Due to Outlier Removal

enthalten in: Therapeutic innovation & regulatory science | 2021

von Fuglsang, A.

10

Structure of the mini-RNA-guided endonuclease CRISPR-Cas12j3

enthalten in: Nature communications | 2021

von Carabias, A. | Fuglsang, A. | Temperini, P. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]